Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux

Zanubrutinib (ZAN) is a Bruton’s tyrosine kinase inhibitor recently approved for the treatment of some non-Hodgkin lymphomas. In clinical trials, ZAN is often combined with standard anthracycline (ANT) chemotherapy. Although ANTs are generally effective, drug resistance is a crucial obstacle that le...

Descripción completa

Detalles Bibliográficos
Autores principales: Čermáková, Lucie, Hofman, Jakub, Laštovičková, Lenka, Havlíčková, Lucie, Špringrová, Ivona, Novotná, Eva, Wsól, Vladimír
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611657/
https://www.ncbi.nlm.nih.gov/pubmed/36297430
http://dx.doi.org/10.3390/pharmaceutics14101994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611657/
https://www.ncbi.nlm.nih.gov/pubmed/36297430
http://dx.doi.org/10.3390/pharmaceutics14101994

Ejemplares similares